UPC: Sanofi v Amgen lands front of queue at new court
The Unified Patent Court (UPC) may be less than a week old but it is already set to be the latest stage for the long-running dispute between Sanofi and Amgen concerning antibody patents.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
5 December 2022 Sunrise period extended over concerns about access to court’s case management system | New period and start date announced by Klaus Grabinski and Johannes Karcher | Full details of new timings.
10 March 2023 Unified Patent Court temporarily removes some functionality from opt-out system for ‘privacy and security’ reasons | New guidance also given on registration of representatives.
20 December 2024 WIPR has published Trademarks Rankings for this year highlighting top firms and practitioners in the US | New firms included in 2024 listing which covers contentious and non-contentious work.